NCT07052578
Aggressive Disease Treatment Patterns and CtDNA HRR evaluatiON in High-volume metastatiC hORmone-sensitive Prostate Cancer in Russian FeDeration
Recruiting · Not specified · AstraZeneca · registry updated 2026-08-18
Inclusion and exclusion lines below are quoted from ClinicalTrials.gov. No match score is shown, because a score needs a person's age, biomarkers, and treatment dates. Confirm the record with the study team.
A multicentre observational study on treatment patterns and ctDNA HRR evaluation in aggressive high-volume metastatic hormone-sensitive prostate cancer in Russian Federation
Inclusion
- Male patients aged ≥ 18 years old;
- Signed ICF, including consent for blood samples ctDNA and ctDNA-based HRRm testing;
- Metastatic hormone-sensitive prostate cancer (mHSPC) (de novo or progressed from earlier stages);
- High-aggressive disease (Gleason 8-10);
- High-volume disease (according to CHAARTED trial criteria: presence of 4 and more (≥4) bone metastases (including at least one (≥1) outside the vertebral column/pelvis) and/or 1 and more (≥1) visceral metastasis);
- Availability of source medical documentation;
Exclusion
- Participation in any interventional trial since the mPC diagnosis.
- Progression to mCRPC.